1.
Merola J, Sofen H, Thaci D, Paul C, Imafuku S, Banerjee S, Armstrong A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2021Nov.5 [cited 2022May18];5(6):s36. Available from: https://www.jofskin.org/index.php/skin/article/view/1387